玻璃体内注射地塞米松治疗糖尿病性黄斑水肿：一项初步研究。
Intravitreal dexamethasone for diabetic macular edema: a pilot study.
作者信息
Chan Carmen K M, Mohamed Shaheeda, Lee Vincent Y W, Lai Timothy Y Y, Shanmugam Mahesh P, Lam Dennis S C
机构信息
Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
出版信息
Ophthalmic Surg Lasers Imaging. 2010 Jan-Feb;41(1):26-30. doi: 10.3928/15428877-20091230-05.
BACKGROUND AND OBJECTIVE
To determine the response and safety profile of intravitreal dexamethasone in treating diabetic macular edema.
PATIENTS AND METHODS
In this prospective pilot study, 12 eyes of 12 patients with diabetic macular edema were randomized to receive a single injection of 0.4 mg (n = 6) or 0.8 mg (n = 6) of intravitreal dexamethasone. The outcome measures were changes in best-corrected visual acuity and central foveal thickness on optical coherence tomography. Side effects were monitored.
RESULTS
The 3-month results were reported. In both dosage groups, there were transient improvements in best-corrected visual acuity and central foveal thickness, but the changes were not significant at any time point (best-corrected visual acuity: P > or = 0.14; central foveal thickness: P > or = .08). No significant side effects were observed, except one eye developed a peak intraocular pressure of greater than 21 mm Hg.
CONCLUSION
A single injection of intravitreal dexamethasone (0.4 or 0.8 mg) did not have significant beneficial effects on diabetic macular edema within 3 months from injection in this small pilot study.
背景与目的
确定玻璃体内注射地塞米松治疗糖尿病性黄斑水肿的疗效和安全性。
患者与方法
在这项前瞻性试点研究中，将12例糖尿病性黄斑水肿患者的12只眼随机分为两组，分别接受单次玻璃体内注射0.4毫克（n = 6）或0.8毫克（n = 6）地塞米松。观察指标为最佳矫正视力的变化以及光学相干断层扫描测量的中心凹厚度。监测副作用。
结果
报告了3个月的结果。两个剂量组的最佳矫正视力和中心凹厚度均有短暂改善，但在任何时间点变化均无统计学意义（最佳矫正视力：P≥0.14；中心凹厚度：P≥0.08）。除1只眼眼压峰值大于21毫米汞柱外，未观察到明显副作用。
结论
在这项小型试点研究中，单次玻璃体内注射地塞米松（0.4毫克或0.8毫克）在注射后3个月内对糖尿病性黄斑水肿未产生明显有益效果。
Zotero 插件